Evaluation of Upadacitinib in Adolescent and Adult Patients With Moderate to Severe Atopic Dermatitis (Eczema)- Measure Up 1 (Measure Up 1)

The objective of this study is to assess the efficacy and safety of upadacitinib for the treatment of adolescent and adult participants with moderate to severe Atopic Dermatitis (AD) who are candidates for systemic therapy.


Study Type: Interventional  (Clinical Trial)
Estimated Enrollment: 810 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Phase 3 Randomized, Placebo-Controlled, Double-Blind Study to Evaluate Upadacitinib in Adolescent and Adult Subjects With Moderate to Severe Atopic Dermatitis
Actual Study Start Date: August 13, 2018
Estimated Primary Completion Date: December 20, 2019
Estimated Study Completion Date: May 6, 2022

Arms:
- Experimental: Arm A (Upadacitinib Dose A is administered once daily.)
- Experimental: Arm B (Upadacitinib Dose B is administered once daily.)
- Experimental: Arm C (Placebo administered once daily followed by Upadacitinib Dose A once daily.)
- Experimental: Arm D (Placebo administered once daily followed by Upadacitinib Dose B once daily.